Su Young Kim

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Matthew S. Davids, Andrew W. Roberts, John F. Seymour et al. · Journal of Clinical Oncology · 2017 · 737 citations · Full text

Immunology, Pathology, Pharmacotherapy +17

Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking <i>KIT</i> and <i>PDGFRA</i> mutations

Katherine A. Janeway, Su Young Kim, Maya Lodish et al. · Proceedings of the National Academy of Sciences · 2010 · 603 citations · Full text

Complex Ii Activity, Succinate Dehydrogenase, Somatic Variant +14

Succinate Dehydrogenase Mutation Underlies Global Epigenomic Divergence in Gastrointestinal Stromal Tumor

Jonathan Keith Killian, Su Young Kim, Markku Miettinen et al. · Cancer Discovery · 2013 · 345 citations · Full text

Engineering, Genetics, Pathology +17

Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models

James G. Taylor, Adam Cheuk, Patricia Tsang et al. · Journal of Clinical Investigation · 2009 · 322 citations · Full text

Human Rhabdomyosarcomas, Xenotransplanted Models, Cancer Biology +17

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

John F. Seymour, Shuo Ma, Danielle M. Brander et al. · The Lancet Oncology · 2017 · 321 citations · Full text

Phase 1B, Lymphoid Neoplasia, Hematological Malignancy +10